A Study of WVT078 in Patients With Multiple Myeloma (MM)
Status:
Recruiting
Trial end date:
2023-12-08
Target enrollment:
Participant gender:
Summary
The design of a phase I, open-label, dose finding study was chosen in order to establish a
safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in
patients relapses and/or refractory Multiple Myeloma (MM)